OBJECTIVE: Phagocyte-derived myeloperoxidase (MPO) and pro-inflammatory high density lipoprotein (HDL) associate with rheumatoid arthritis (RA), but the link between MPO and HDL has not been systematically examined. In this study, we investigated whether MPO can oxidise HDL and determined MPO-specific oxidative signature by apoA-1 by peptide mapping in RA subjects with and without known cardiovascular disease (CVD). METHODS: Two MPO oxidation products, 3-chlorotyrosine and 3-nitrotyrosine, were quantified by tandem mass spectrometry (MS/MS) in in vitro model system studies and in plasma and HDL derived from healthy controls and RA subjects. MPO levels and cholesterol efflux were determined. Site-specific nitration and chlorination of apoA-1 peptides were quantified by MS/MS. RESULTS: RA subjects demonstrated higher levels of MPO, MPO-oxidised HDL and diminished cholesterol efflux. There was marked increase in MPO-specific 3-chlorotyrosine and 3-nitrotyrosine content in HDL in RA subjects consistent with specific targeting of HDL, with increased nitration in RA subjects with CVD. Cholesterol efflux capacity was diminished in RA subjects and correlated inversely with HDL 3-chlorotyrosine suggesting a mechanistic role for MPO. Nitrated HDL was elevated in RACVD subjects compared with RA subjects without CVD. Oxidative peptide mapping revealed site-specific unique oxidation signatures on apoA-1 for RA subjects with and without CVD. CONCLUSIONS: We report an increase in MPO-mediated HDL oxidation that is regiospecific in RA and accentuated in those with CVD. Decreased cholesterol efflux capacity due to MPO-mediated chlorination is a potential mechanism for atherosclerosis in RA and raises the possibility that oxidant resistant forms of HDL may attenuate this increased risk.
OBJECTIVE: Phagocyte-derived myeloperoxidase (MPO) and pro-inflammatory high density lipoprotein (HDL) associate with rheumatoid arthritis (RA), but the link between MPO and HDL has not been systematically examined. In this study, we investigated whether MPO can oxidise HDL and determined MPO-specific oxidative signature by apoA-1 by peptide mapping in RA subjects with and without known cardiovascular disease (CVD). METHODS: Two MPO oxidation products, 3-chlorotyrosine and 3-nitrotyrosine, were quantified by tandem mass spectrometry (MS/MS) in in vitro model system studies and in plasma and HDL derived from healthy controls and RA subjects. MPO levels and cholesterol efflux were determined. Site-specific nitration and chlorination of apoA-1peptides were quantified by MS/MS. RESULTS: RA subjects demonstrated higher levels of MPO, MPO-oxidised HDL and diminished cholesterol efflux. There was marked increase in MPO-specific 3-chlorotyrosine and 3-nitrotyrosine content in HDL in RA subjects consistent with specific targeting of HDL, with increased nitration in RA subjects with CVD. Cholesterol efflux capacity was diminished in RA subjects and correlated inversely with HDL 3-chlorotyrosine suggesting a mechanistic role for MPO. Nitrated HDL was elevated in RACVD subjects compared with RA subjects without CVD. Oxidative peptide mapping revealed site-specific unique oxidation signatures on apoA-1 for RA subjects with and without CVD. CONCLUSIONS: We report an increase in MPO-mediated HDL oxidation that is regiospecific in RA and accentuated in those with CVD. Decreased cholesterol efflux capacity due to MPO-mediated chlorination is a potential mechanism for atherosclerosis in RA and raises the possibility that oxidant resistant forms of HDL may attenuate this increased risk.
Authors: Christina Charles-Schoeman; Yuen Yin Lee; Victor Grijalva; Sogol Amjadi; John FitzGerald; Veena K Ranganath; Mihaela Taylor; Maureen McMahon; Harold E Paulus; Srinivasa T Reddy Journal: Ann Rheum Dis Date: 2012-01-20 Impact factor: 19.103
Authors: I Torsteinsdóttir; L Hâkansson; R Hällgren; B Gudbjörnsson; N G Arvidson; P Venge Journal: Rheumatology (Oxford) Date: 1999-12 Impact factor: 7.580
Authors: R Zhang; M L Brennan; X Fu; R J Aviles; G L Pearce; M S Penn; E J Topol; D L Sprecher; S L Hazen Journal: JAMA Date: 2001-11-07 Impact factor: 56.272
Authors: Stephan Baldus; Christopher Heeschen; Thomas Meinertz; Andreas M Zeiher; Jason P Eiserich; Thomas Münzel; Maarten L Simoons; Christian W Hamm Journal: Circulation Date: 2003-09-02 Impact factor: 29.690
Authors: Ling Li; Gurkan Bebek; Stephen F Previs; Jonathan D Smith; Rovshan G Sadygov; Arthur J McCullough; Belinda Willard; Takhar Kasumov Journal: J Proteome Res Date: 2016-08-05 Impact factor: 4.466
Authors: Tomáš Vaisar; Chongren Tang; Ilona Babenko; Patrick Hutchins; Jake Wimberger; Anthony F Suffredini; Jay W Heinecke Journal: J Lipid Res Date: 2015-05-20 Impact factor: 5.922
Authors: Michelle J Ormseth; Patricia G Yancey; Suguru Yamamoto; Annette M Oeser; Tebeb Gebretsadik; Ayumi Shintani; MacRae F Linton; Sergio Fazio; Sean S Davies; L Jackson Roberts; Kasey C Vickers; Paolo Raggi; Valentina Kon; C Michael Stein Journal: IJC Metab Endocr Date: 2016-08-28
Authors: Subramaniam Pennathur; Anuradha Vivekanandan-Giri; Morgan L Locy; Tejaswini Kulkarni; Degui Zhi; Lixia Zeng; Jaeman Byun; Joao A de Andrade; Victor J Thannickal Journal: Am J Respir Crit Care Med Date: 2016-04-15 Impact factor: 21.405
Authors: Michelle J Ormseth; Patricia G Yancey; Joseph F Solus; S Louis Bridges; Jeffrey R Curtis; MacRae F Linton; Sergio Fazio; Sean S Davies; L Jackson Roberts; Kasey C Vickers; Valentina Kon; C Michael Stein Journal: Arthritis Rheumatol Date: 2016-09 Impact factor: 10.995
Authors: Carolyne K Smith; Nickie L Seto; Anuradha Vivekanandan-Giri; Wenmin Yuan; Martin P Playford; Zerai Manna; Sarfaraz A Hasni; Rui Kuai; Nehal N Mehta; Anna Schwendeman; Subramaniam Pennathur; Mariana J Kaplan Journal: Ann Rheum Dis Date: 2016-08-19 Impact factor: 19.103